Selecta Biosciences Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Selecta Biosciences stock.
View analyst ratings for Selecta Biosciences or view top-rated stocks.

Wall Street analysts have given Selecta Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Selecta Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Selecta Biosciences.

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its quarterly earnings data on Wednesday, August, 11th. The company reported $0.04 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.16. The company had revenue of $19.66 million for the quarter, compared to analysts' expectations of $10.83 million.
View Selecta Biosciences' earnings history.

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SELB shares have increased by 34.3% and is now trading at $4.15.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 12-month price targets for Selecta Biosciences' stock. Their forecasts range from $3.50 to $13.00. On average, they anticipate Selecta Biosciences' stock price to reach $8.10 in the next twelve months. This suggests a possible upside of 95.2% from the stock's current price.
View analysts' price targets for Selecta Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Selecta Biosciences include Revance Therapeutics (RVNC), ADC Therapeutics (ADCT), NGM Biopharmaceuticals (NGM), Trillium Therapeutics (TRIL), Deciphera Pharmaceuticals (DCPH), Cassava Sciences (SAVA), Nuvalent (NUVL), Centessa Pharmaceuticals (CNTA), IVERIC bio (ISEE), uniQure (QURE), Zymeworks (ZYME), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX), MorphoSys (MOR) and Global Blood Therapeutics (GBT).
View all of SELB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Selecta Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.91%), Vanguard Group Inc. (4.45%), Nuveen Asset Management LLC (1.90%), Marshall Wace North America L.P. (1.78%), JPMorgan Chase & Co. (1.63%) and BVF Inc. IL (1.50%). Company insiders that own Selecta Biosciences stock include Carsten Brunn, Lloyd P Johnston, Peter G Traber, Timothy A Springer and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences.

SELB stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., BVF Inc. IL, Goldman Sachs Group Inc., Morgan Stanley, Morgan Stanley, Citigroup Inc., Northern Trust Corp, and Susquehanna International Group LLP. Company insiders that have sold Selecta Biosciences company stock in the last year include Carsten Brunn, and Lloyd P Johnston.
View insider buying and selling activity for Selecta Biosciences or view top insider-selling stocks.

SELB stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BlackRock Inc., Bank of Montreal Can, Marshall Wace LLP, Marshall Wace LLP, Nuveen Asset Management LLC, JPMorgan Chase & Co., and Geode Capital Management LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Peter G Traber, Timothy A Springer, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences or or view top insider-buying stocks.

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SELB stock can currently be purchased for approximately $4.15.

Selecta Biosciences has a market capitalization of $477.58 million and generates $16.60 million in revenue each year. The company earns $-68,880,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

Selecta Biosciences employs 44 workers across the globe.

The official website for Selecta Biosciences is selectabio.com.

Selecta Biosciences is headquartered at 65 Grove Street, Watertown MA, 02472.

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at (617) 923-1400 or via email at [email protected]